


CV of KATRD International Conference 2020

Name	Yoichi Nakanishi	
Country	Japan	
Organization	Kitakyushu City Hospital Organization	
Current Position	President	

Educational Background

Postdoctoral training	National Cancer Institute, Bethesda, Maryland, USA. (1985-1987) Field of Study: Cellular Biology of Lung Cancer Preceptor: Dr. James L Mulshine
Ph.D.	Kyushu University, Fukuoka, Japan. Thesis title: Study on autocrine growth factors of small cell lung cancer. (February , January 18, 1990)
M.D.	Faculty of Medicine, Kyushu University, Fukuoka, Japan (March 31, 1980)

Professional Experiences

Current

President: Kitakyushu City Hospital Organization
Principal: Kitakyushu Municipal School of Nursing

Previous

Professor: Division of Respiratory Medicine, Department of Clinical Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan (May 2003-March 2019)

Director: Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University (October 2003- March 2019)

Vice-director, Kyushu University Hospital (April 2014-March 2018)

Chief: Center of Clinical and Translational Research, Kyushu University Hospital (October 2003- March 2019)

Professor: Digital Patients, Digital Medicine Initiative, Kyushu University (April 2006-March 2010)

Assistant Professor: Division of Respiratory Medicine, Kyushu University Hospital (December 1994-April 1999)

Instructor: Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushu University (May 1990-December 1994)

Instructor: Department of Internal Medicine, Saga Medical School (September 1987-April 1990, April 1984-September 1985)

Guest Researcher and Fogarty Fellow, Navy Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland (September 1985-August 1987)

Senior Resident: Division of Respiratory Medicine, Kyushu University Hospital (June 1982-March 1984)

Resident: Department of Internal Medicine, Kyushu Kohsei Nenkin Hospital (June 1981-May 1982)

Resident: Division of Respiratory Medicine, Kyushu University Hospital (June 1980-May 1981)

Professional Organizations

Asian Pacific Society of Respiriology (Chairman of Lung Cancer Assembly 2007-2013, Member of executive committee 2009-2013, 2016-present, Treasurer 2016-2019, Secretary General 2018-2019, President 2019-present)

American Thoracic Society

American College of Chest Physician (Fellow, International Governor)

European Respiratory Society

Asian Pacific Lung Cancer Group (Board member 2010-2013, Conference President of APLCC 2012)

Japanese Society of Internal Medicine (Fellow 1991-2019, Senior member 2019-present)

Japan Respiratory Society (Member of Board of Directors -2019, Conference President 2017, Senior member 2019-present)

Japanese Society for Tuberculosis (Member of Board of Directors -2019, Senior member 2019-present)
Japan Lung Cancer Society (Member of Board of Directors -2018, President 2010-2014, Conference President 2016)

Japanese Society of Medical Oncology (Member of Board of Directors -2019, Conference President 2018, Senior member 2019-present)

ARO Council, Japan (President 2014-2019)

Japan Society for Respiratory Endoscopy (Special Member)

Japanese Association for Infectious Diseases (Fellow)

West Japan Oncology Group (Member of Board of Directors 2000-present, President 2009-2015)

Main Scientific Publications

Nakanishi Y, Mulshine JL, Kasprzyk PG, Natale R, Maneckjee R, Avis I, Treston AM, Gazdar AF, Minna JD, Cuttitta F. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. *J Clin Invest*, 82:354-359, 1988

Pei X-H, Nakanishi Y, Takayama K, Bai F, Inoue K, Hara N. Benzo[a]pyrene activates the human p53 gene through induction of NF- κ B activity. *J Biol Chem*, 274:35240-35246, 1999

Nakanishi Y, Pei X-H, Takayama K, Bai F, Izumi M, Kimotsuki K, Inoue K, Minami T, Wataya H, Hara H. Polycyclic aromatic hydrocarbon carcinogens increase ubiquitination of p21 protein after the stabilization of p53 and the expression of p21. *Am J Respir Cell Mol Biol*, 22:747-754, 2000

Inoshima N, Nakanishi Y, Minami, T, Izumi M, Takayama K, Yoshino I, Hara N. The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. *Clin Cancer Res*, 8:3480-3486, 2002

Fujita M, Ya Q, Ouchi H, Nakashima N, Hamada N, Hagimoto N, Kuwano K, Mason RJ, Nakanishi Y. Retinoic acid fails to reverse emphysema in adult mouse models
Thorax, 59:224-230, 2004

Hamada N, Kuwano K, Yamada M, Hagimoto N, Hiasa K, Egashira K, Nakashima N, Maeyama T, Yoshimi M, Nakanishi Y. 1Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. *J Immunol*, 175:1224-1231, 2005

Ebi E, Semba H, Tokunaga S, Takayama K, Wataya H, Kuraki T, Yamamoto H, Akamine S, Okamoto I, Nakanishi Y (Lung Oncology Group in Kyushu Japan)
A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
J Thorac Oncol, 10:1166-1171, 2008

Harada C, Kawaguchi T, Ogata-Suetsugu S, Yamada M, Hamada N, Maeyama T, Souzaki R, Tajiri T, Taguchi T, Kuwano K, Nakanishi Y. EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium. *Am J Respir Crit Care Med*, 183:743-751, 2011

Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N; West Japan Oncology Group. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Lancet Oncol, 16:1630-1638, 2015

Yanagihara T, Sanematsu F, Sato T, Uruno T, Duan X, Tomino T, Harada Y, Watanabe M, Wang Y, Tanaka Y, Nakanishi Y, Suyama M, Yoshinori F. Intronic regulation of Aire expression by Jmjd6 for self-tolerance induction in the thymus. *Nat Commun*, 6:8820, 2015

Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, Satouchi M, Iwamoto Y, Kanehara M, Fujimoto D, Ikeda N, Murakami H, Daga H, Oguri T, Goto I, Imamura F, Sugawara S, Saka H, Nogami N, Negoro S, Nakagawa K, Nakanishi Y. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. *J Clin Oncol*, 34:3248-3257, 2016

Iwama E, Okamoto I, Yabuuchi H, Takayama K, Harada T, Matsuo Y, Tokunaga S, Baba E, Nakanishi Y. Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae. *J Thorac Oncol*, 11:1586-1590, 2016

Sasaki T, Seto T, Yamanaka T, Kunitake N, Shimizu J, Kodaira T, Nishio M, Kozuka T, Takahashi T, Harada H, Yoshimura N, Tsutsumi S, Kitajima H, Kataoka M, Ichinose Y, Nakagawa K, Nishimura Y, Yamamoto N, Nakanishi Y. A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L. *Br J Cancer*, 119(6):675-682, 2018

Iwama E, Sakai K, Azuma K, Harada D, Nosaki K, Hotta K, Nishio M, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I. Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing. *Cancer Sci*, 109:3921-3933, 2018